About Phathom Pharma (PHAT)
Phathom Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing treatments for gastrointestinal (GI) diseases. Its product candidate, vonoprazan, is an oral small molecule pot... Read more
- USD4.02
- USD4.17
- USD3.97
- USD19.71
- -35.50%
- 55M
- 920.78k
- 1.29M
- 281M
- 3.81
- -55.60%
Stock News
4 hours ago
Alphabet’s blowout earnings may mark the peak for this year — but the stock’s still a good buy
MarketWatch
yesterday
Alphabet expects 'slight headwind' to ads business this year, executives say
CNBC
yesterday
Jim Cramer credits this week's rally to earnings and restraint from the White House
CNBC
yesterday
The AI data center trade is coming back to life, but a key test remains
CNBC
Unlock More Stock Analysis & Reports
Access detailed stock analysis from LSEG including analyst price target estimates.
